This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ecolab (ECL) Sells Surgical Solutions Business to Medline
by Zacks Equity Research
Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Are Basic Materials Stocks Lagging Eldorado Gold (EGO) This Year?
by Zacks Equity Research
Here is how Eldorado Gold Corporation (EGO) and Ecolab (ECL) have performed compared to their sector so far this year.
How to Find Strong Basic Materials Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Ecolab (ECL) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Ecolab (ECL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ecolab (ECL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of 1.20% and 1.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 3 Medical Device Stocks Hit Earnings This Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.
Countdown to Ecolab (ECL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Ecolab (ECL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
What's in Store for Materials ETFs in Q2 Earnings?
by Sweta Killa
Going into the Q2 earnings season, earnings releases from the sector giants will determine the movement of these funds.
Suzano (SUZ) to Buy 2 Mills From Pactiv Evergreen for $110M
by Zacks Equity Research
Suzano (SUZ) signs an agreement with Pactiv Evergreen to acquire two of its US industrial facilities.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
Barrick (GOLD) Announces Strategic Plans for Loulo-Gounkoto
by Zacks Equity Research
Barrick (GOLD) emphasizes the importance of sustaining the Loulo-Gounkoto gold mining complex, with a significant economic contribution to Mali.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Royal Gold (RGLD) Issues Stream Segment Sales Update for Q2
by Zacks Equity Research
Royal Gold (RGLD) sells 52,600 gold equivalent ounces in the June-end quarter of 2024.
DuPont (DD) Tyvek Richmond Facility Gets ISCC+ Certification
by Zacks Equity Research
DuPont's (DD) global integration of ISCC PLUS certification into Tyvek production coincides with the company's commitment to empowering clients on their road to net zero emissions.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Here's Why You Should Add H.B. Fuller (FUL) to Your Portfolio
by Zacks Equity Research
H.B. Fuller (FUL) presents a substantial investment opportunity with robust earnings outperformance and promising growth prospects.
ArcelorMittal (MT)-Partners Begin Carbon Capture Trial in Ghent
by Zacks Equity Research
ArcelorMittal (MT), MHI and D-CRBN are trialing plasma technology at Gent to convert CO2 into carbon monoxide for steel and chemical production, aiming to reduce emissions.